Det verkar som att du använder inkognito mode/privat surfningsläge eller en annonsblockerare, vilket kan försämra din upplevelse på webbplatsen. För en bättre upplevelse, inaktivera annonsblockerare och visa webbplatsen i icke-privat surfningsläge.
Our fully automated PD-L1 solutions empower choices by identifying patients who are most likely to benefit from specific therapies. The VENTANA PD-L1 (SP142) Assay and the VENTANA PD-L1 (SP263) Assay generate reliable results that direct patients to multiple immunotherapies. We support pathologist with the tools to successfully implement these assays into their laboratory workflow and interpret them proficiently.
These assays are used to identify patients more likely to respond to immunotherapies or to determine PD-L1 status to inform physicians considering treatment options for cancer patients.
